Moderna shares up 60% as melanoma vaccine trial with Merck succeeds
Interim analysis shows goals were met for recurrence and preventing cancer spread
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.businesslive.co.za — the content belongs to Business Day.
